Vaccine · Immune activation, directed at SARS-CoV-2 spike protein · developed by Tonix Pharmaceuticals
TNX-2120 represents the SARS-CoV-2 spike protein and is administered intradermally. It is studied for detecting delayed-type hypersensitivity reactions to SARS-CoV-2 in individuals exposed to the virus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05216510 | Phase 1 | Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in… | Terminated | TNXP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNXP page.
See TNXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNXP catalysts and pipeline →